Ian Clark Sells 264,800 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Ian Clark sold 264,800 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $29.73, for a total value of $7,872,504.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Olema Pharmaceuticals Trading Down 1.2%

Shares of Olema Pharmaceuticals stock opened at $27.34 on Thursday. The firm has a market cap of $1.88 billion, a PE ratio of -14.62 and a beta of 1.87. The stock has a fifty day moving average price of $18.92 and a 200-day moving average price of $10.68. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.03 and a quick ratio of 8.03. Olema Pharmaceuticals, Inc. has a 1 year low of $2.86 and a 1 year high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.05). Equities research analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current year.

Institutional Investors Weigh In On Olema Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Ameritas Investment Partners Inc. increased its holdings in Olema Pharmaceuticals by 55.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company’s stock worth $26,000 after buying an additional 2,168 shares in the last quarter. ProShare Advisors LLC raised its stake in Olema Pharmaceuticals by 21.1% during the 2nd quarter. ProShare Advisors LLC now owns 14,766 shares of the company’s stock worth $63,000 after acquiring an additional 2,569 shares during the period. Bank of America Corp DE raised its position in shares of Olema Pharmaceuticals by 0.4% during the 3rd quarter. Bank of America Corp DE now owns 802,304 shares of the company’s stock valued at $7,855,000 after purchasing an additional 2,802 shares during the period. FNY Investment Advisers LLC raised its holdings in Olema Pharmaceuticals by 100.0% during the second quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company’s stock valued at $42,000 after acquiring an additional 5,000 shares during the period. Finally, Russell Investments Group Ltd. purchased a new position in Olema Pharmaceuticals in the 3rd quarter worth approximately $53,000. Institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals News Summary

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Seeking Alpha reiterates a “Strong Buy” on Olema driven by initiation of the OPERA‑02 pivotal trial and promising combo data (palazestrant + KISQALI), highlighting OPERA‑01 readout in 2H‑2026 and OPERA‑02 topline in 2028 as key value catalysts. Seeking Alpha – Strong Buy on OPERA‑02
• Positive Sentiment: Several sell‑side firms have raised targets and reiterated buys (Goldman, Citi, JPMorgan, UBS), lifting the consensus price target (~$40.50 average), which supports upside if clinical milestones land.
• Neutral Sentiment: Reported short interest data shows effectively zero shares short and a 0.0 days‑to‑cover figure, indicating short sellers are not currently positioned to amplify moves (data appears to show no measurable short interest for December).
• Negative Sentiment: Director Ian T. Clark sold 264,800 shares on Dec. 19 at ~$29.73 (≈$7.87M), a large director‑level disposal that can raise governance/lockup concern and pressure the stock. SEC Form 4 – Clark sale 12/19/2025
• Negative Sentiment: Naseem Zojwalla executed multiple large sales (100,000; 70,000; 99,509 shares across Dec. 19–23), reducing his stake materially and generating roughly $7.5M+ in proceeds across those trades. SEC Form 4 – Zojwalla sales
• Negative Sentiment: David C. Myles sold 51,000 shares on Dec. 19 at ~$30.46 (~$1.55M), trimming his holding by ~8.5%—another insider sale contributing to near‑term selling pressure. SEC Form 4 – Myles sale 12/19/2025

Analyst Ratings Changes

OLMA has been the topic of several analyst reports. Oppenheimer upped their price target on Olema Pharmaceuticals from $45.00 to $48.00 and gave the company an “outperform” rating in a research report on Thursday, December 11th. Citigroup lifted their price target on shares of Olema Pharmaceuticals from $21.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. The Goldman Sachs Group boosted their target price on Olema Pharmaceuticals from $26.00 to $38.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. JPMorgan Chase & Co. increased their price target on shares of Olema Pharmaceuticals from $29.00 to $32.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Finally, HC Wainwright lifted their price objective on Olema Pharmaceuticals from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $40.50.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.